Current need in lung cancer

Carlos Gil Ferreira

Interview with Carlos Gil Ferreira, MD, PhD

Director Clinical and Translational Research, Instituto Nacional de Câncer, Rio de Janeiro, Brazil

We have been treating lung cancer in the same way for the last years, and the results have not improved so much. What has happened in fact is a new understanding of the disease, especially in the biology of the disease.

Lung cancer has a very complex biology and what we call ‘carcinogenesis’, the process that leads to tumour formation. In lung cancer, different from other tumour types, you have many mutations in different genes and, within the same tumour, the same patient, you have different alterations and the understanding of this biology is still not good enough so far, so we have to improve that.

Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.

† Not an official event of the 2012 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Boehringer Ingelheim on